selectION, Inc. to Present Update on Clinical Progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024 Best-in-class Kv1.3 blocker has successfully completed a Phase 1b trial in atopic dermatitis patientsPipeline molecule to treat T cell mediated autoimmune diseases San Diego, CA, USA, and...